{"product_id":"dechra-laverdia-ca1-verdinexor-tablets-dogs-2-5mg","title":"Laverdia-CA1 2.5 mg (50 tablets)","description":"\u003cp align=\"center\"\u003e\u003cimg src=\"https:\/\/shopify-images-bucket.s3.us-west-2.amazonaws.com\/rx-map.jpg\" class=\"img-responsive\" alt=\"RX MAP\" width=\"700\"\u003e\u003c\/p\u003e\n\u003ch2\u003eOral Lymphoma Treatment Tablets for Dogs Support\u003c\/h2\u003e\n\u003ch3\u003e\u003cstrong\u003eProduct Description\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp\u003eLaverdia-CA1 is an orally administered cancer medication indicated for lymphoma treatment in dogs. It contains verdinexor, which inhibits the growth of cancer cells by interfering with nuclear export proteins. This treatment has received conditional authorization from the U.S. Food and Drug Administration for veterinary use under the supervision of a qualified professional.\u003c\/p\u003e\n\u003cp\u003e\u003cspan style=\"color: rgb(255, 42, 0);\"\u003eNOTE: For generic medications, the product image shown may not reflect the actual item received. Generic medications can vary in size, color, and shape between orders depending on the manufacturer. Additionally, your medication may arrive packaged in a HardyPaw Pharmacy vial.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch3\u003e\u003cstrong\u003eBenefits\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eTargets Cancer Cells\u003c\/strong\u003e: Selectively inhibits nuclear export protein CRM1, helping retain tumor suppressor proteins in the nucleus to limit cancer progression.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eOral Administration:\u003c\/strong\u003e The tablet formulation enables dosing at home under veterinary supervision, reducing the need for frequent visits to the clinic for injectable chemotherapy treatments.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eFlexible Dosing Schedule:\u003c\/strong\u003e Typically given twice a week, with dose modifications based on the patient's tolerance, allowing veterinarians to customize therapy to meet individual patient requirements.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eClinically Evaluated:\u003c\/strong\u003e Field studies confirming conditional FDA approval have shown a measurable response in dogs with newly diagnosed or relapsed lymphoma.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eConvenient Strength Options:\u003c\/strong\u003e Offered in various tablet strengths to facilitate precise weight-based dosing for a broad spectrum of dog sizes.\u003cbr\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3\u003e\u003cstrong\u003eIngredients\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp\u003eVerdinexor 2.5 mg per tablet\u003c\/p\u003e\n\u003ch3\u003e\u003cstrong\u003eHow to Use\u003c\/strong\u003e\u003c\/h3\u003e\n\u003ch4\u003e\u003cstrong\u003eRecommended-Dosage Chart\u003c\/strong\u003e\u003c\/h4\u003e\n\u003ctable style=\"width: 52.54%; height: 101px;\"\u003e\n\u003ctbody\u003e\n\u003ctr style=\"height: 55.1989px;\"\u003e\n\u003ctd width=\"132\" style=\"width: 23.2207%; height: 55.1989px;\"\u003e\n\u003cp\u003e\u003cstrong\u003eDog Weight (kg)\u003c\/strong\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003ctd width=\"113\" style=\"width: 19.9806%; height: 55.1989px;\"\u003e\n\u003cp\u003e\u003cstrong\u003eInitial Dose (mg\/kg)\u003c\/strong\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003ctd width=\"83\" style=\"width: 14.5804%; height: 55.1989px;\"\u003e\n\u003cp\u003e\u003cstrong\u003eFrequency\u003c\/strong\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003ctd width=\"236\" style=\"width: 41.0412%; height: 55.1989px;\"\u003e\n\u003cp\u003e\u003cstrong\u003eNotes\u003c\/strong\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr style=\"height: 55.1989px;\"\u003e\n\u003ctd width=\"132\" style=\"width: 23.2207%; height: 55.1989px;\"\u003e\n\u003cp\u003e≥ 9 kg\u003c\/p\u003e\n\u003c\/td\u003e\n\u003ctd width=\"113\" style=\"width: 19.9806%; height: 55.1989px;\"\u003e\n\u003cp\u003e1.25 mg\/kg\u003c\/p\u003e\n\u003c\/td\u003e\n\u003ctd width=\"83\" style=\"width: 14.5804%; height: 55.1989px;\"\u003e\n\u003cp\u003eTwice weekly\u003c\/p\u003e\n\u003c\/td\u003e\n\u003ctd width=\"236\" style=\"width: 41.0412%; height: 55.1989px;\"\u003e\n\u003cp\u003eMinimum 72 hours between doses.\u003c\/p\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr style=\"height: 55.1989px;\"\u003e\n\u003ctd width=\"132\" style=\"width: 23.2207%; height: 55.1989px;\"\u003e\n\u003cp\u003eAfter 2 weeks, if tolerated\u003c\/p\u003e\n\u003c\/td\u003e\n\u003ctd width=\"113\" style=\"width: 19.9806%; height: 55.1989px;\"\u003e\n\u003cp\u003e1.5 mg\/kg\u003c\/p\u003e\n\u003c\/td\u003e\n\u003ctd width=\"83\" style=\"width: 14.5804%; height: 55.1989px;\"\u003e\n\u003cp\u003eTwice weekly\u003c\/p\u003e\n\u003c\/td\u003e\n\u003ctd width=\"236\" style=\"width: 41.0412%; height: 55.1989px;\"\u003e\n\u003cp\u003eDose increases based on tolerance.\u003c\/p\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr style=\"height: 55.1989px;\"\u003e\n\u003ctd width=\"132\" style=\"width: 23.2207%; height: 55.1989px;\"\u003e\n\u003cp\u003eIf adverse reactions occur\u003c\/p\u003e\n\u003c\/td\u003e\n\u003ctd width=\"113\" style=\"width: 19.9806%; height: 55.1989px;\"\u003e\n\u003cp\u003e1 mg\/kg minimum\u003c\/p\u003e\n\u003c\/td\u003e\n\u003ctd width=\"83\" style=\"width: 14.5804%; height: 55.1989px;\"\u003e\n\u003cp\u003eTwice weekly\u003c\/p\u003e\n\u003c\/td\u003e\n\u003ctd width=\"236\" style=\"width: 41.0412%; height: 55.1989px;\"\u003e\n\u003cp\u003eDose reduction or interruption may be required.\u003c\/p\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003ch4\u003e\u003cstrong\u003eDosage \u0026amp; Administration Instructions\u003c\/strong\u003e\u003c\/h4\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eFeed Before Dosing\u003c\/strong\u003e: Administer tablets immediately after feeding to improve drug absorption and achieve more consistent therapeutic exposure levels.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eTwice Weekly Schedule\u003c\/strong\u003e: Give orally two times per week with at least seventy-two hours between doses as directed.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eDo Not Crush\u003c\/strong\u003e: Tablets should not be split, crushed, or broken to maintain accurate dosing and safety during administration.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eProtective Handling\u003c\/strong\u003e: Wear chemotherapy-resistant disposable gloves when handling tablets to avoid accidental exposure to the medication.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eVeterinary Prescription\u003c\/strong\u003e: This medication is restricted to use by or on the order of a licensed veterinarian only.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eDisclaimer:\u003c\/strong\u003e This dosage information is provided by the manufacturer. Always consult your veterinarian before administering or adjusting any supplement for your pet.\u003c\/p\u003e\n\u003ch3\u003e\u003cstrong\u003eAdditional Information\u003c\/strong\u003e\u003c\/h3\u003e\n\u003ch4\u003e\u003cstrong\u003ePrecautions\u003c\/strong\u003e\u003c\/h4\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eHealth Monitoring\u003c\/strong\u003e: Dogs should be monitored frequently for blood and serum chemistry abnormalities during treatment initiation and maintenance periods.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eMedical Conditions\u003c\/strong\u003e: Safety has not been evaluated in dogs with serious infections, organ disease, diabetes, or clinically relevant hypercalcemia.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eBreeding Restrictions\u003c\/strong\u003e: Do not use in pregnant, lactating, or breeding dogs due to potential fertility effects and developmental risks.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eDrug Interactions\u003c\/strong\u003e: Concurrent use with medications undergoing glutathione conjugation metabolism should be minimized to avoid metabolic interference risks.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eYoung Dogs\u003c\/strong\u003e: Safety has not been established in dogs younger than seven months of age, according to manufacturer information.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch4\u003e\u003cstrong\u003ePossible Side Effects\u003c\/strong\u003e\u003c\/h4\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eGastrointestinal Signs:\u003c\/strong\u003e Reduced appetite, nausea, diarrhea, and loss of weight are some of the side effects that might require supportive care from a veterinarian.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eLethargy:\u003c\/strong\u003e During treatment, dogs might experience fatigue, weakness, or elevated temperature, as observed in clinical studies.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eBlood Abnormalities\u003c\/strong\u003e: Changes such as thrombocytopenia, anemia, or leukocyte abnormalities have been reported during treatment in some dogs.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eKidney Changes\u003c\/strong\u003e: Increased thirst, urination abnormalities, or urinary infections may occur as noted in treated dogs.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eLiver Effects\u003c\/strong\u003e: Elevated liver enzymes or bilirubin-related changes have been observed in some treated animals.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch4\u003e\u003cstrong\u003eStorage Information\u003c\/strong\u003e\u003c\/h4\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eRoom Temperature:\u003c\/strong\u003e Maintain a stable temperature of 20°C to 25°C for best stability.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eOriginal Container: \u003c\/strong\u003eStore in the original container with a desiccant and a child-proof cap to ensure product quality.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eSecure Location:\u003c\/strong\u003e Keep it in a safe place away from pets, children, food prep areas, and other human medications.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3\u003e\u003cstrong\u003eShipping \u0026amp; Return\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp\u003eWe offer ground, express, priority, and international delivery; see our \u003ca href=\"https:\/\/hardypaw.com\/pages\/shipping-policies\"\u003eshipping policy\u003c\/a\u003e for details.\u003c\/p\u003e\n\u003cp\u003eFor return instructions or product concerns, please refer to our detailed \u003ca href=\"https:\/\/hardypaw.com\/policies\/refund-policy\"\u003erefund policy\u003c\/a\u003e. \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePrescription items are NON-RETURNABLE and NON-REFUNDABLE. \u003c\/strong\u003e \u003c\/p\u003e\n\u003ch2\u003eFrequently Asked Questions\u003c\/h2\u003e\n\u003ch3\u003e\u003cstrong\u003eQ1: What is Laverdia-CA1 used for in dogs?\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp\u003e\u003cstrong\u003eAns:\u003c\/strong\u003e Laverdia-CA1 is an oral anticancer drug prescribed for dogs with lymphoma. It contains verdinexor, which inhibits proteins that allow cancer cells to grow. The FDA has conditionally approved this therapy for veterinary use under the guidance of a professional.\u003c\/p\u003e\n\u003ch3\u003e\u003cstrong\u003eQ2: How is Laverdia-CA1 administered to dogs?\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp\u003e\u003cstrong\u003eAns:\u003c\/strong\u003e The medication is given orally, typically twice per week with at least seventy-two hours between doses. Dogs should be fed before administration to improve absorption. Tablets must not be crushed or split, and dosing adjustments are made by a veterinarian based on tolerance.\u003c\/p\u003e\n\u003ch3\u003e\u003cstrong\u003eQ3: How effective is Laverdia-CA1 for canine lymphoma?\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp\u003e\u003cstrong\u003eAns:\u003c\/strong\u003e Clinical studies in the field showed an objective response rate of about thirty-four percent in dogs with newly diagnosed or relapsed lymphoma. The median time to disease progression varied, with some dogs having longer responses based on individual factors and how well they tolerated treatment.\u003c\/p\u003e\n\u003ch3\u003e\u003cstrong\u003eQ4: What side effects should pet owners watch for?\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp\u003e\u003cstrong\u003eAns:\u003c\/strong\u003e Frequent side effects can include reduced appetite, nausea, diarrhea, fatigue, and weight loss. There have also been changes in blood parameters, kidney function, and raised liver enzymes. Canines in treatment should be monitored closely by a veterinarian for any troubling clinical signs.\u003c\/p\u003e\n\u003ch3\u003e\u003cstrong\u003eQ5: Are there any safety precautions for handling this medication?\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp\u003e\u003cstrong\u003eAns:\u003c\/strong\u003e Yes, protective chemotherapy-resistant gloves should be worn when handling tablets or waste from treated dogs. Pregnant or nursing individuals should avoid contact and should store away from the reach of children to avoid accidental exposure.\u003c\/p\u003e\n\u003ch2\u003eClinical Research:\u003c\/h2\u003e\n\u003col\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/animaldrugsatfda.fda.gov\/adafda\/app\/search\/public\/document\/downloadFoi\/10270\"\u003eFDA: Laverdia-CA1 Approval Overview\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/vcahospitals.com\/know-your-pet\/lymphoma-in-dogs\"\u003eVCA Animal Hospitals: Lymphoma in Dogs\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/uwveterinarycare.wisc.edu\/oncology\/\"\u003eUniversity of Wisconsin Veterinary Care – Oncology Services\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/www.petmd.com\/dog\/conditions\/cancer\/c_dg_lymphoma\"\u003ePetMD: Dog Cancer Overview\u003c\/a\u003e\u003c\/li\u003e\n\u003c\/ol\u003e","brand":"Dechra","offers":[{"title":"Default Title","offer_id":43263037636769,"sku":"LBL-7004-00","price":168.99,"currency_code":"USD","in_stock":false}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0593\/2446\/5313\/files\/laverdia2.5.png?v=1696526415","url":"https:\/\/hardypaw.com\/products\/dechra-laverdia-ca1-verdinexor-tablets-dogs-2-5mg","provider":"HardyPaw","version":"1.0","type":"link"}